Acadia Pharmaceuticals Launches Daybue (trofinetide) for the Treatment of Rett Syndrome in the US
Shots:
- The company reported the commercial availability of Daybue for Rett syndrome in adult & pediatric patients aged ≥2yrs. in the US. Daybue is supplied as a strawberry-flavored oral solution containing 200mg of trofinetide per mL
- Daybue was approved in the US for Rett syndrome, based on a P-III study (LAVENDER) study in female patients aged 5-20yrs. Trofinetide showed an increased branching of dendrites and synaptic plasticity signals in animal studies
- The company offers a patient support program i.e., Acadia Connect that provides the access to eligible patients with Daybue & offers personal assistance, financial resources & prescription support to patients & caregivers starting & continuing appropriate Daybue therapy
Ref: BusinessWire | Image: Acadia
Related Post:- Acadia’s Daybue (trofinetide) Receives the US FDA’s Approval for Rett Syndrome in Adult and Pediatric Patients Aged ≥2Years
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
